Literature DB >> 31019902

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Atsushi Hiraoka1, Takashi Kumada2, Kunihiko Tsuji3, Koichi Takaguchi4, Ei Itobayashi5, Kazuya Kariyama6, Hironori Ochi7, Kazuto Tajiri8, Masashi Hirooka9, Noritomo Shimada10, Toru Ishikawa11, Yoshihiko Tachi12, Toshifumi Tada2, Hidenori Toyoda2, Kazuhiro Nouso6, Kouji Joko7, Yoichi Hiasa9, Kojiro Michitaka1, Masatoshi Kudo13.   

Abstract

BACKGROUND/AIM: The frequency of hepatocellular carcinoma (HCC) in patients with good hepatic reserve function has been increasing in Japan along with the progression of antiviral therapies and aging of the society. We evaluated the usefulness of modified albumin-bilirubin (ALBI) grade as a tool for assessment of hepatic reserve function. MATERIALS/
METHODS: We enrolled 6,649 naïve HCC patients treated from 2000 to 2017 and divided them into training (Ehime Prefecture group: E group, n = 2,357) and validation (validation group: V group, n = 4,292) cohorts. Child-Pugh classification and ALBI and modified ALBI (mALBI) grading were compared using with Japan Integrated Staging (JIS), ALBI-TNM (ALBI-T), and mALBI-T scores, which were calculated based on TNM stage and each assessment tool, retrospectively.
RESULTS: In the E group, Akaike's Information Criterion (AIC) and c-index values for mALBI-T (13,725.2/0.744) were better as compared to those of ALBI-T (13,772.6/0.733) and JIS score (13,874.7/0.720), with similar results observed in the V group (mALBI-T: 27,727.4/0.760; ALBI-T: 27,817.8/0.750; JIS: 27,807.5/0.748). Although there were some significant differences between the groups with regard to clinical background factors (age, etiology, tumor size, tumor number, treatment modalities), for all patients the AIC and c-index values of mALBI-T (45,327.1/0.755) were also better than those of ALBI-T (45,467.7/0.744) and JIS scores (45,555.8/0.739), indicating its superior stratification ability and prognostic predictive value in patients with HCC.
CONCLUSION: The detailed stratification ability of mALBI grade for hepatic reserve function is suitable for the recent trend of HCC patients, while mALBI-T may provide a more accurate predictive value than existing total staging scoring systems.

Entities:  

Keywords:  ALBI-T score; Albumin-bilirubin grade; Hepatocellular carcinoma; Japan Integrated Staging score; Modified ALBI; Prognosis; mALBI-T score

Year:  2018        PMID: 31019902      PMCID: PMC6465715          DOI: 10.1159/000488778

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  34 in total

1.  Management of hepatocellular carcinoma.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

2.  Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

Review 3.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

4.  Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.

Authors:  Yasuhiro Asahina; Kaoru Tsuchiya; Nobuharu Tamaki; Itsuko Hirayama; Tomohiro Tanaka; Mitsuaki Sato; Yutaka Yasui; Takanori Hosokawa; Ken Ueda; Teiji Kuzuya; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Masayuki Kurosaki; Nobuyuki Enomoto; Namiki Izumi
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

5.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

6.  Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma.

Authors:  Atsushi Hiraoka; Kojiro Michitaka; Teru Kumagi; Kiyotaka Kurose; Takahide Uehara; Masashi Hirooka; Yoshimasa Yamashita; Yoshikazu Kubo; Hiroaki Miyaoka; Hidehito Iuchi; Shinichi Okada; Masaki Ohmoto; Kazuhisa Yamamoto; Norio Horiike; Morikazu Onji
Journal:  Oncol Rep       Date:  2005-06       Impact factor: 3.906

7.  Assessment of liver function for safe hepatic resection.

Authors:  Yasuji Seyama; Norihiro Kokudo
Journal:  Hepatol Res       Date:  2009-02       Impact factor: 4.288

8.  Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan.

Authors:  Masatoshi Makuuchi; Norihiro Kokudo; Shigeki Arii; Shunji Futagawa; Shuichi Kaneko; Seiji Kawasaki; Yutaka Matsuyama; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Yukihisa Saida; Tadatoshi Takayama; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2008-01       Impact factor: 4.288

9.  Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications.

Authors:  Atsushi Hiraoka; Norio Horiike; Yoshimasa Yamashita; Yohei Koizumi; Kazuhiro Doi; Yasunori Yamamoto; Aki Hasebe; Soichi Ichikawa; Makoto Yano; Yasunao Miyamoto; Tomoyuki Ninomiya; Yoichi Otomi; Masahiro Kokame; Takuaki Iwamura; Yoshihiro Ishimaru; Ichiro Sogabe; Kenichi Kashihara; Saburo Nishiura; Hiromi Ootani; Kazuhito Takamura; Hideki Kawasaki
Journal:  Hepatogastroenterology       Date:  2008 Nov-Dec

10.  Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan.

Authors:  Iwao Ikai; Shigeki Arii; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Morito Monden; Masatoshi Kudo
Journal:  Hepatol Res       Date:  2007-09       Impact factor: 4.288

View more
  52 in total

1.  Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.

Authors:  Atsushi Hiraoka; Takashi Kumada; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Keisuke Yokohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-10-18       Impact factor: 11.740

Review 2.  Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis.

Authors:  Gauri Mishra; Ammar Majeed; Anouk Dev; Guy D Eslick; David J Pinato; Hirofumi Izumoto; Atsushi Hiraoka; Teh-Ia Huo; Po-Hong Liu; Philip J Johnson; Stuart K Roberts
Journal:  J Gastrointest Cancer       Date:  2022-05-30

3.  Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-12-08       Impact factor: 11.740

4.  Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Hidenori Toyoda; Satoshi Yasuda; Kunihiko Tsuji; Takeshi Hatanaka; Satoru Kakizaki; Atsushi Naganuma; Toru Ishikawa; Toshifumi Tada; Koichi Takaguchi; Ei Itobayashi; Noritomo Shimada; Hiroshi Shibata; Takaaki Tanaka; Akemi Tsutsui; Takuya Nagano; Michitaka Imai; Shinichiro Nakamura; Kazuhiro Nouso
Journal:  Oncology       Date:  2021-11-29       Impact factor: 2.935

5.  Association of the Modified ALBI Grade With Endoscopic Findings of Gastroesophageal Varices.

Authors:  Yuho Miyamoto; Hirayuki Enomoto; Hiroki Nishikawa; Takashi Nishimura; Yoshinori Iwata; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 6.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

7.  What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

Authors:  Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Kazuya Kariyama; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-02-25       Impact factor: 11.740

8.  EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.

Authors:  Kazuya Kariyama; Kazuhiro Nouso; Atsushi Hiraoka; Akiko Wakuta; Ayano Oonishi; Teiji Kuzuya; Hidenori Toyoda; Toshifumi Tada; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Koichi Takaguchi; Akemi Tsutsui; Noritomo Shimada; Masatoshi Kudo; Takashi Kumada
Journal:  Liver Cancer       Date:  2020-10-23       Impact factor: 11.740

9.  Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.

Authors:  Atsushi Hiraoka; Masaya Kato; Kaori Marui; Taisei Murakami; Kei Onishi; Tomoko Adachi; Junko Matsuoka; Hidetaro Ueki; Takeaki Yoshino; Miho Tsuruta; Toshihiko Aibiki; Tomonari Okudaira; Taira Kuroda; Ryuichiro Iwasaki; Yoshifumi Suga; Hideki Miyata; Tomoyuki Ninomiya; Masashi Hirooka; Masanori Abe; Bunzo Matsuura; Kojiro Michitaka; Yoichi Hiasa
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

10.  Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization.

Authors:  Osman Öcal; Juozas Kupčinskas; Egidijus Morkunas; Holger Amthauer; Kerstin Schütte; Peter Malfertheiner; Heinz Josef Klümpen; Christian Sengel; Julia Benckert; Ricarda Seidensticker; Bruno Sangro; Moritz Wildgruber; Maciej Pech; Peter Bartenstein; Jens Ricke; Max Seidensticker
Journal:  EJNMMI Res       Date:  2021-06-02       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.